InvestSMART

ePAT Technologies Limited (ASX: EPT) - Announcements

Current share price for EPT : $0.062 0.006 (8.82%)+

ASX company news and announcements for ePAT Technologies Limited (EPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ePAT Technologies Limited (EPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ePAT Technologies Limited (EPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ePAT Technologies Limited (EPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Response to ASX Query re Share Price 14 Jul 2005 2:41PM $0.520 $0.062 fallen by 88.08%
- Private Placement raises A$3.5 Million 7 Jul 2005 9:16AM $0.405 $0.062 fallen by 84.69%
- Current market conditions unattractive for capital raising 11 May 2005 4:29PM $0.500 $0.062 fallen by 87.60%
- To List on AIM/Capital Raising & EGM Notification 30 Mar 2005 6:13PM $0.610 $0.062 fallen by 89.84%
- Receives Ethic Approval for Phase II Endpoint Study-Sydney 7 Mar 2005 10:58AM $0.780 $0.062 fallen by 92.05%
- PMLE trial of Melanotan to start in Finland 1 Mar 2005 10:54AM $0.760 $0.062 fallen by 91.84%
- In-Licenses OraDisc A from Access Pharmaceuticals USA 8 Feb 2005 10:28AM $0.820 $0.062 fallen by 92.44%
- UK regulatory appr obtained for topical trial of Melanotan 24 Jan 2005 10:31AM $0.880 $0.062 fallen by 92.95%
- Private Placement Raises A$2.08 Million 15 Dec 2004 2:15PM $0.860 $0.062 fallen by 92.79%
- EpiTan reports on dose escalation study 15 Dec 2004 12:11PM $0.860 $0.062 fallen by 92.79%
- Files provisional patent in the United States 12 Aug 2004 9:21AM $0.910 $0.062 fallen by 93.19%
- Private Placement raises $7.98 million 11 Aug 2004 8:58AM $0.850 $0.062 fallen by 92.71%
- Sustained-release clinical trial res with smaller implant 6 Jul 2004 1:10PM $0.900 $0.062 fallen by 93.11%
- Completes Level One ADR program 1 Jul 2004 1:39PM $0.940 $0.062 fallen by 93.40%
- Response to ASX Price Query 14 Apr 2004 9:23AM $0.860 $0.062 fallen by 92.79%
- European clinical trials for PMLE to be expanded 26 Mar 2004 9:13AM $0.760 $0.062 fallen by 91.84%
- Half Yearly Report & Half Year Accounts 25 Feb 2004 4:17PM $0.730 $0.062 fallen by 91.51%
- Implant trial exceeds expectation 11 Feb 2004 9:35AM $0.740 $0.062 fallen by 91.62%
- Phase II Trial Results 28 Nov 2003 8:32AM $0.650 $0.062 fallen by 90.46%
- FDA Meeting 11 Nov 2003 8:42AM $0.710 $0.062 fallen by 91.27%
- Commitments Test Entity - First Quarter Report 30 Oct 2003 2:41PM $0.730 $0.062 fallen by 91.51%
- Phase IIb trial results 28 Oct 2003 8:50AM $0.780 $0.062 fallen by 92.05%
- Colaboration with pSiMedica Limited 24 Sep 2003 9:22AM $0.590 $0.062 fallen by 89.49%
- Preliminary Final Report & Full Year Accounts 8 Sep 2003 11:56AM $0.620 $0.062 fallen by 90%
- Raises $7.4 million through placement of shares 25 Aug 2003 10:03AM $0.620 $0.062 fallen by 90%

101 - 125 of 128 results

Page 5 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.